aTYR PHARMA INC Increase (Decrease) in Contract with Customer, Liability
aTYR PHARMA INC (ATYR) reported Increase (Decrease) in Contract with Customer, Liability of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-14.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2023-03-14
- aTYR PHARMA INC increase (decrease) in contract with customer, liability for the quarter ending 2020-12-31 was -$53.00K.
- aTYR PHARMA INC increase (decrease) in contract with customer, liability for the quarter ending 2020-09-30 was -$148.00K.
- aTYR PHARMA INC increase (decrease) in contract with customer, liability for the quarter ending 2020-06-30 was $58.00K.
- aTYR PHARMA INC increase (decrease) in contract with customer, liability for the quarter ending 2020-03-31 was -$65.00K, a 110.32% decline year-over-year.
- aTYR PHARMA INC increase (decrease) in contract with customer, liability for fiscal 2022 was $0.00.
- aTYR PHARMA INC increase (decrease) in contract with customer, liability for fiscal 2021 was $0.00.
- aTYR PHARMA INC increase (decrease) in contract with customer, liability for fiscal 2020 was -$208.00K, a 200.00% decline from fiscal 2019.
- aTYR PHARMA INC increase (decrease) in contract with customer, liability for fiscal 2019 was $208.00K.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-14 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-03-14 | |||
| 2020-12-31 | -$53.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | -$201.00K derived: sum of 2 quarters · filed 2023-03-14 | -$143.00K derived: sum of 3 quarters · filed 2023-03-14 | -$208.00K 10-K · filed 2023-03-14 |
| 2020-09-30 | -$148.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$90.00K derived: sum of 2 quarters · filed 2021-11-12 | -$155.00K 10-Q · filed 2021-11-12 | -$299.00K derived: sum of 4 quarters · filed 2022-03-15 |
| 2020-06-30 | $58.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | -$7.00K 10-Q · filed 2021-08-11 | -$151.00K derived: sum of 3 quarters · filed 2022-03-15 | -$335.00K derived: sum of 4 quarters · filed 2022-03-15 |
| 2020-03-31 | -$65.00K 10-Q · filed 2021-05-14 | -$209.00K derived: sum of 2 quarters · filed 2022-03-15 | -$393.00K derived: sum of 3 quarters · filed 2022-03-15 | -$487.00K derived: sum of 4 quarters · filed 2022-03-15 |
| 2019-12-31 | -$144.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | -$328.00K derived: sum of 2 quarters · filed 2022-03-15 | -$422.00K derived: sum of 3 quarters · filed 2022-03-15 | $208.00K 10-K · filed 2022-03-15 |
| 2019-09-30 | -$184.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | -$278.00K derived: sum of 2 quarters · filed 2020-11-13 | $352.00K 10-Q · filed 2020-11-13 | |
| 2019-06-30 | -$94.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | $536.00K 10-Q · filed 2020-08-13 | ||
| 2019-03-31 | $630.00K 10-Q · filed 2020-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |